User login
WASHINGTON – What can explain the failure of SYMPLICITY HTN-3? After clinical success in reducing blood pressure by 20-30 mm HG in patients with resistant hypertension, the renal denervation treatment showed no significant reduction in the first randomized trial in which control patients underwent sham operations.
According to two top hypertension experts, trial investigator Dr. George Bakris and Dr. Prakash Deedwania, physiology, behavior, and technology come to mind for starters, as explored in Part 1 of our interview.
WASHINGTON – What can explain the failure of SYMPLICITY HTN-3? After clinical success in reducing blood pressure by 20-30 mm HG in patients with resistant hypertension, the renal denervation treatment showed no significant reduction in the first randomized trial in which control patients underwent sham operations.
According to two top hypertension experts, trial investigator Dr. George Bakris and Dr. Prakash Deedwania, physiology, behavior, and technology come to mind for starters, as explored in Part 1 of our interview.
WASHINGTON – What can explain the failure of SYMPLICITY HTN-3? After clinical success in reducing blood pressure by 20-30 mm HG in patients with resistant hypertension, the renal denervation treatment showed no significant reduction in the first randomized trial in which control patients underwent sham operations.
According to two top hypertension experts, trial investigator Dr. George Bakris and Dr. Prakash Deedwania, physiology, behavior, and technology come to mind for starters, as explored in Part 1 of our interview.
At ACC 14
